chapter 3

Introduction to Psychotropic Drug Targets

  • Major Classes of Targets:

    • Twelve-transmembrane region transporter: ~30% of psychotropic drugs.

    • Seven-transmembrane region G-protein linked receptor: ~30% of psychotropic drugs.

    • Enzyme: ~10% of psychotropic drugs.

    • Four-transmembrane region ligand-gated ion channel: ~20% of psychotropic drugs.

    • Six-transmembrane region voltage-gated ion channel: ~10% of psychotropic drugs.

Ligand-Gated Ion Channels

  • Key Ligand-Gated Ion Channels Directly Targeted by Psychotropic Drugs:

    • Neurotransmitter: Acetylcholine

    • Receptor subtype: α4β2-nicotinic receptors

    • Pharmacological action: Partial agonist

    • Therapeutic action: Smoking cessation.

    • Neurotransmitter: GABA

    • Receptor subtype: GABA-A benzodiazepine receptors

      • Pharmacological action: Full agonist, phasic inhibition

      • Therapeutic action: Anxiolytic.

    • GABA-A non-benzodiazepine PAM sites

      • Pharmacological action: Full agonist, phasic inhibition

      • Therapeutic action: Improves insomnia.

    • GABA-A neurosteroid sites (benzodiazepine insensitive)

      • Pharmacological action: Full agonist, tonic inhibition

      • Therapeutic action: Post-partum depression, Rapid-acting antidepressant, Anesthetic.

    • Neurotransmitter: Glutamate

    • Receptor subtype: NMDA NAM channels sites/Mg²⁺ sites

      • Pharmacological action: Antagonist

      • Therapeutic action: Procognitive in Alzheimer disease.

    • NMDA open channel sites

      • Pharmacological action: Antagonist

      • Therapeutic action: Dissociative hallucinogen, Anesthetic, Pseudobulbar affect, Agitation in Alzheimer disease, Rapid-acting antidepressant, Treatment-resistant depression.

    • Neurotransmitter: Serotonin

    • Receptor subtype: 5HT3

      • Pharmacological action: Antagonist

      • Therapeutic action: Procognitive, Antidepressant, Reduce chemotherapy-induced emesis.

Structurally Diverse Channels

Pentameric Ligand-Gated Ion Channels (pLGICs)

  • Subtypes include:

    • Nicotinic acetylcholine (nAChR)

    • Type 3 serotonin (5-HT3R)

    • GABA type A (GABAAR)

    • Glycine receptors (GlyR)

  • Structure: Comprised of five subunits arranged around a central pore, allowing ion fluxes that modify the membrane potential and neuronal excitability.

  • Conserved Architecture: Recent structural data shows a cylinder-shape, with:

    • Extracellular domain (ECD): Contains the agonist-binding site.

    • Four transmembrane domains (TM1–4): Shape the ion pore.

    • Large intracellular domain (ICD): Between TM3 and TM4.

    • Short extracellular C-terminal region.

Tetrameric Ligand-Gated Ion Channels (Ionotropic Glutamate Receptors)

  • Examples:

    • Glutamate receptors: AMPA (GluR1–4 subunits), KAINATE (GluR5–7, KA1–2 subunits), NMDA (NMDAR1, NMDAR2A–D, NMDAR3A subunits).

  • Structure: Consists of 3 transmembrane regions, 1 re-entrant loop, and 4 subunits.

  • Implications: Involved in nervous system development; dysfunction linked to diseases like Alzheimer’s, Parkinson’s, schizophrenia, depression, brain trauma, and stroke.

Agonist and Antagonist Interaction

The Agonist Spectrum

  • Agonist: Naturally activates the channel.

  • Partial agonist: Binds to the receptor but causes lesser activation than a full agonist.

  • Antagonist: Binds to the receptor but does not activate it. Can stabilize the channel into a resting state.

  • Inverse agonist: Stabilizes the channel in an inactive form by reducing the channel's activity further than the baseline.

Receptor Desensitization

  • Desensitization Process: Prolonged exposure to an agonist can lead to desensitization characterized by:

    1. Uncoupling: Occurs within seconds to minutes after agonist application.

    2. Internalization: Decreased receptor density in response to continual stimulation (minutes).

    3. Downregulation/Degradation: Decrease of receptor availability (hours to days).

Positive and Negative Allosteric Modulators (PAMs and NAMs)

Positive Allosteric Modulator (PAM)

  • Mechanism: Enhances the effect of the agonist, leading to greater ion influx when both agonist and PAM are present.

  • Example: Benzodiazepines (e.g., Valium) enhance GABA-A receptor activity, useful for anxiety and insomnia.

  • GABA-A Receptor Activation: When GABA binds to its site, the channel opens and allows chloride ions (Cl⁻) into the cell, leading to hyperpolarization and reduced excitability.

Negative Allosteric Modulator (NAM)

  • Mechanism: Reduces the efficacy of the agonist, leading to decreased ion conductance when both agonist and NAM are present.

  • Example: Flumazenil is a NAM at the benzodiazepine site on GABA-A receptors, used to counteract benzodiazepine overdoses.

Action Potentials and Ion Channel Function

  • Ionic Components of an Action Potential:

    • Sodium (Na⁺)

    • Calcium (Ca²⁺)

    • Potassium (K⁺)

  • Voltage-Sensitive Sodium Channel (VSSC) States:

    • Open: Allows Na⁺ influx.

    • Inactivated: Channel cannot open; resets the channel.

    • Closed: The channel is in a resting state but can open again.

  • Function of Voltage-Sensitive Calcium Channels (VSCCs): Trigger neurotransmitter release upon activation during action potentials.

Dysregulation and Neurological Disorders

  • Consequences of Dysregulation: Alterations in calcium channel activity can lead to neurological disorders including:

    • Epilepsy

    • Migraine

    • Chronic pain

  • Importance of Voltage-Gated Calcium Channels: They are pharmacological targets for these neurological conditions due to their role in neurotransmitter release and neuronal excitability regulation.

Summary of Voltage-Sensitive Calcium Channels (VSCCs)

  • Types of VSCCs and Their Functions:

    • L Type (Cav 1.2, 1.3): Gene expression, synaptic integration.

    • N Type (Cav 2.2): Transmitter release, synaptic integration.

    • P/Q Type (Cav 2.1): Transmitter release, synaptic integration.

    • R Type (Cav 2.3): Transmitter release, synaptic integration.

    • T Type (Cav 3.1, 3.2, 3.3): Pacemaking, repetitive firing, synaptic integration.